FI3395423T3 - Vuotaneen affiniteettipuhdistusligandin poistaminen - Google Patents

Vuotaneen affiniteettipuhdistusligandin poistaminen Download PDF

Info

Publication number
FI3395423T3
FI3395423T3 FIEP18168494.5T FI18168494T FI3395423T3 FI 3395423 T3 FI3395423 T3 FI 3395423T3 FI 18168494 T FI18168494 T FI 18168494T FI 3395423 T3 FI3395423 T3 FI 3395423T3
Authority
FI
Finland
Prior art keywords
protein
chromatography medium
anion exchange
recombinant protein
exchange matrix
Prior art date
Application number
FIEP18168494.5T
Other languages
English (en)
Finnish (fi)
Inventor
Samuel Ray Trejo
Robert Perry Brake
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50424772&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI3395423(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of FI3395423T3 publication Critical patent/FI3395423T3/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/18—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns
    • B01D15/1864—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns
    • B01D15/1871—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns placed in series
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FIEP18168494.5T 2013-03-14 2014-03-11 Vuotaneen affiniteettipuhdistusligandin poistaminen FI3395423T3 (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361785038P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
FI3395423T3 true FI3395423T3 (fi) 2023-11-02

Family

ID=50424772

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP18168494.5T FI3395423T3 (fi) 2013-03-14 2014-03-11 Vuotaneen affiniteettipuhdistusligandin poistaminen

Country Status (17)

Country Link
US (3) US20160024144A1 (enExample)
EP (3) EP2969099B2 (enExample)
JP (1) JP6457479B2 (enExample)
AU (1) AU2014240596B2 (enExample)
CA (1) CA2904411A1 (enExample)
CY (1) CY1120353T1 (enExample)
DK (2) DK3395423T3 (enExample)
ES (2) ES2674697T5 (enExample)
FI (1) FI3395423T3 (enExample)
HU (2) HUE064450T2 (enExample)
LT (2) LT3395423T (enExample)
MX (2) MX365501B (enExample)
PL (2) PL2969099T5 (enExample)
PT (2) PT3395423T (enExample)
SI (2) SI3395423T1 (enExample)
TR (1) TR201809050T4 (enExample)
WO (1) WO2014159441A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3395423T1 (sl) 2013-03-14 2023-12-29 Amgen Inc. Odstranjevanje izluženega liganda za afinitetno čiščenje
TWI596107B (zh) * 2013-06-25 2017-08-21 卡地拉保健有限公司 單株抗體之新穎純化方法
MX2016016318A (es) * 2014-06-13 2017-06-12 Lupin Atlantis Holdings Sa Proceso para la purificacion de la proteina de fusion.
CN105214341B (zh) * 2015-09-17 2017-12-15 广州康盛生物科技有限公司 组合型吸附柱及其制备方法
EP3436473A4 (en) * 2016-03-29 2019-10-23 Navya Biologicals Pvt. Ltd. METHOD FOR PURIFYING FC FUSION PROTEINS
US12516102B1 (en) 2017-02-09 2026-01-06 Bracco Suisse Sa Process for the purification of soluble PSGL-1 protein variants
CN118047854B (zh) * 2024-02-26 2024-08-02 武汉鹰达生物科技有限公司 一种人载脂蛋白a-i的分离纯化方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
AU588819B2 (en) 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
DE3811042A1 (de) 1988-03-31 1989-10-19 Merck Patent Gmbh Ionenaustauscher
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
EP0939121B2 (de) 1989-09-12 2007-12-26 AHP Manufacturing B.V. TFN-bindende Proteine
US6204363B1 (en) 1989-10-16 2001-03-20 Amgen Inc. Stem cell factor
US5272064A (en) 1989-12-19 1993-12-21 Amgen Inc. DNA molecules encoding platelet-derived growth factor B chain analogs and method for expression thereof
US5149792A (en) 1989-12-19 1992-09-22 Amgen Inc. Platelet-derived growth factor B chain analogs
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
PT672141E (pt) 1992-10-23 2003-09-30 Immunex Corp Metodos de preparacao de proteinas oligomericas soluveis
US5554512A (en) 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
DE4333821A1 (de) 1993-10-04 1995-04-06 Merck Patent Gmbh Ionenaustauscher
US5981713A (en) 1994-10-13 1999-11-09 Applied Research Systems Ars Holding N.V. Antibodies to intereleukin-1 antagonists
DE19501726A1 (de) 1995-01-20 1996-07-25 Merck Patent Gmbh Polymerisationsfähige Derivate von Polyamiden
DK1666591T3 (da) 1995-06-29 2011-05-23 Immunex Corp Cytokin der inducerer apoptose
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
WO1997049754A1 (de) 1996-06-21 1997-12-31 Merck Patent Gmbh Polymerisationsfähige derivate von polyamiden
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
ATE478732T1 (de) 1997-06-18 2010-09-15 Merck Patent Gmbh Verwendung monolithischer sorbentien für präparative chromatographische trennverfahren
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
AU1920301A (en) 1999-11-17 2001-05-30 Immunex Corporation Receptor activator of nf-kappa b
FR2824568B1 (fr) * 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
ES2322945T5 (es) * 2001-12-21 2012-10-17 Immunex Corporation Métodos para purficación de proteína
EP1869065B1 (en) * 2005-03-11 2020-05-06 Wyeth LLC A method of weak partitioning chromatography
CN102887955A (zh) * 2006-04-05 2013-01-23 艾博特生物技术有限公司 抗体纯化
SI2078071T1 (sl) * 2006-11-08 2015-05-29 Wyeth Llc Racionalno zasnovana gojišča za celično kulturo
NZ592095A (en) * 2008-10-20 2013-01-25 Abbott Lab Isolation and purification of il-12 and tnf-alpha antibodies using protein a affinity chromatography
WO2010147686A2 (en) * 2009-03-11 2010-12-23 Wyeth Llc Methods of purifying small modular immunopharmaceutical proteins
US9428546B2 (en) * 2010-07-30 2016-08-30 Pfizer Inc. Tandem purification of proteins
US20140128577A1 (en) * 2011-06-24 2014-05-08 Dr. Reddy's Laboratories Limited Purification of chimeric protein
DK2729482T3 (en) * 2011-07-08 2018-05-07 Merck Sharp & Dohme PROCEDURE FOR CLEANING FC-FUSION PROTEIN
BR112014010580B1 (pt) * 2011-11-04 2021-01-12 Zymeworks, Inc. constructo de fc heteromultimérico isolado, composição, uso de um constructo de fc heteromultimérico isolado, composição de ácido nucléico e método para expressar o constructo de fc heteromultimérico isolado
SG10201701224UA (en) * 2012-03-12 2017-04-27 Merck Patent Gmbh Removal of protein aggregates from biopharmaceutical preparations in a flowthrough mode
SI3395423T1 (sl) 2013-03-14 2023-12-29 Amgen Inc. Odstranjevanje izluženega liganda za afinitetno čiščenje

Also Published As

Publication number Publication date
PT2969099T (pt) 2018-07-05
PL2969099T3 (pl) 2018-10-31
EP2969099B1 (en) 2018-04-25
WO2014159441A1 (en) 2014-10-02
EP3395423A1 (en) 2018-10-31
LT2969099T (lt) 2018-09-10
JP2016513643A (ja) 2016-05-16
US11192919B2 (en) 2021-12-07
PT3395423T (pt) 2023-11-14
MX2015011994A (es) 2015-12-01
US20160024144A1 (en) 2016-01-28
DK2969099T4 (da) 2022-03-14
ES2964601T3 (es) 2024-04-08
HUE064450T2 (hu) 2024-03-28
SI2969099T1 (sl) 2018-09-28
MX391507B (es) 2025-03-21
HK1220159A1 (en) 2017-04-28
JP6457479B2 (ja) 2019-01-23
AU2014240596A1 (en) 2015-09-24
TR201809050T4 (tr) 2018-07-23
LT3395423T (lt) 2023-12-11
MX365501B (es) 2019-06-05
DK2969099T3 (en) 2018-07-09
ES2674697T5 (es) 2022-04-19
EP4026596A1 (en) 2022-07-13
HUE038565T2 (hu) 2018-10-29
EP3395423B1 (en) 2023-09-20
SI2969099T2 (sl) 2022-04-29
EP2969099A1 (en) 2016-01-20
EP2969099B2 (en) 2021-12-22
ES2674697T3 (es) 2018-07-03
PL3395423T3 (pl) 2024-03-18
SI3395423T1 (sl) 2023-12-29
CY1120353T1 (el) 2019-07-10
MX2019006568A (es) 2019-08-22
PL2969099T5 (pl) 2022-06-13
AU2014240596B2 (en) 2018-09-27
CA2904411A1 (en) 2014-10-02
US11492372B2 (en) 2022-11-08
DK3395423T3 (da) 2023-11-20
US20190085021A1 (en) 2019-03-21
US20220144886A1 (en) 2022-05-12

Similar Documents

Publication Publication Date Title
FI3395423T3 (fi) Vuotaneen affiniteettipuhdistusligandin poistaminen
JP2016513643A5 (enExample)
CY1116129T1 (el) Καθαρισμος αντισωματος με κατιονανταλλακτικη χρωματογραφια
BRPI0611600B8 (pt) método para purificação de uma proteína tendo uma região fc a partir de um líquido fonte compreendendo a proteína e uma ou mais impurezas, e kit
AR074015A1 (es) Purificacion de proteinas acidas utilizando cromatografia de hidroxiapatita ceramica
RU2012130151A (ru) Промывочный раствор и способ промывки для аффинной хроматографии
SE0400501D0 (sv) Antibody purification
RU2014111820A (ru) Способы элиминации вируса
EA201592192A1 (ru) Способ очистки моноклональных антител
SG10201908027QA (en) Use of alkaline washes during chromatography to remove impurities
RU2017101727A (ru) Способы и реагенты для очистки белков
JP2016530533A5 (enExample)
JP2017521389A5 (enExample)
ATE547521T1 (de) Verfahren zur reinigung von nukleinsäure
RU2014130017A (ru) Способы повышения эффективности этапов очистки белка, находящихся ниже по потоку, с использованием мембранной ионообменной хроматографии
JP2018510867A5 (enExample)
JP2015537212A5 (enExample)
EP4371996A3 (en) Methods for purifying antibodies
RU2019109975A (ru) Способы очистки антител
JP2012503170A5 (enExample)
JP2017510305A5 (enExample)
JP2014507368A5 (enExample)
EP4671270A3 (en) Method for purifying antibody having low isoelectric point
Westra et al. Immobilised metal-ion affinity chromatography purification of histidine-tagged recombinant proteins: a wash step with a low concentration of EDTA
JP2016530216A5 (enExample)